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Abstract
Activation of brain melanocortin-4 receptors (MC4-R) by a-melanocyte-stimulating hormone (MSH) or inhibition by agouti-
related protein (AgRP) regulates food intake and energy expenditure and can modulate neuroendocrine responses to
changes in energy balance. To examine the effects of AgRP inhibition on energy balance, a small molecule, non-peptide
compound, TTP2515, developed by TransTech Pharma, Inc., was studied in vitro and in rodent models in vivo. TTP2515
prevented AgRP from antagonizing a-MSH-induced increases in cAMP in HEK 293 cells overexpressing the human MC4-R.
When administered to rats by oral gavage TTP2515 blocked icv AgRP-induced increases in food intake, weight gain and
adiposity and suppression of T4 levels. In both diet-induced obese (DIO) and leptin-deficient mice, TTP2515 decreased food
intake, weight gain, adiposity and respiratory quotient. TTP2515 potently suppressed food intake and weight gain in lean
mice immediately after initiation of a high fat diet (HFD) but had no effect on these parameters in lean chow-fed mice.
However, when tested in AgRP KO mice, TTP2515 also suppressed food intake and weight gain during HFD feeding. In
several studies TTP2515 increased T4 but not T3 levels, however this was also observed in AgRP KO mice. TTP2515 also
attenuated refeeding and weight gain after fasting, an effect not evident in AgRP KO mice when administered at moderate
doses. This study shows that TTP2515 exerts many effects consistent with AgRP inhibition however experiments in AgRP KO
mice indicate some off-target effects of this drug. TTP2515 was particularly effective during fasting and in mice with leptin
deficiency, conditions in which AgRP is elevated, as well as during acute and chronic HFD feeding. Thus the usefulness of
this drug in treating obesity deserves further exploration, to define the AgRP dependent and independent mechanisms by
which TTP2515 exerts its effects on energy balance.
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Introduction
The hypothalamic melanocortin system is a critical regulator of
energy homeostasis in both animals and humans. This system is
comprised of proopiomelanocortin (POMC) and agouti-related
peptide (AgRP) neurons, located in the arcuate nucleus of the
hypothalamus, which project to second-order neurons that express
melanocortin receptors (MC-R); the peptide products of these
neurons interact at the MC-R to regulate energy balance [1,2].
POMC-derived a-melanocyte-stimulating hormone (MSH) is an
agonist for the G-protein coupled MC4-R that reduces food intake
and increases energy expenditure (EE) [3–6]. Oppositely, AgRP
behaves as a potent melanocortin receptor antagonist, and in some
reports, an inverseagonist, that promotespositive energybalance [7–
10].Bothneuronsare targets for leptinand insulinandcan integratea
variety of nutritional andneuronal signals to regulate energy balance
[1].
The role of AgRP in the regulation of energy balance has been
examined in a number of different rodent models. AgRP
expression in the arcuate nucleus is increased during fasting and
in mice with genetic leptin deficiency [11–13]. Both overexpres-
sion of AgRP and intracerebroventricular (icv) AgRP administra-
tion increase food intake, body weight and adiposity, and AgRP
also decreases EE [7,8,14,15], and can mediate some of the
neuroendocrine responses to food deprivation, including suppres-
sion of the hypothalamic-pituitary-thyroid (HPT) axis [8,16–18].
In addition, activation of AgRP neurons using designer
receptors rapidly induces voracious feeding, decreases EE and
increases adiposity [19]. While reduction of hypothalamic AgRP
expression by RNA interference has been shown to increase
metabolic rate and decrease body weight [20], genetic deletion of
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AgRP yields much milder effects, implicating developmental
compensation [18,21]. Postembryonic ablation of AgRP neurons
in mice leads to starvation in adults but not neonates [22],
however the starvation phenotype appears to be due to the loss of
c-aminobutyric acid (GABA) from AgRP neurons, rather than the
loss of AgRP peptide [23]. To date, there have been no reports of
a specific pharmacological inhibitor of the AgRP peptide. Such an
inhibitor could be used to help elucidate the extent to which AgRP
contributes to energy homeostasis and neuroendocrine responses
to food deprivation. An AgRP inhibitor also has the potential to be
utilized in a therapeutic capacity, particularly under conditions in
which AgRP is elevated. The drug development of MSH agonists
has been complicated by a number of side effects, including
hypertension, possibly related to the extensive projection of
POMC neurons and wide distribution of brain MC-Rs [24–28].
In contrast, AgRP neuronal projections are more limited to brain
areas involved with energy balance, making AgRP an attractive
target for pharmacological inhibition [27–29].
TransTech Pharma, Inc. has developed a series of potent, small
molecular weight, non-peptide, compounds that selectively inhibit
AgRP’s antagonist activity. These compounds displayed high
brain penetration after oral administration, and when studied
in vitro prevented AgRP from antagonizing MC4-R signaling.
Studies on one of these compounds showed that it was specific for
AgRP, as it did not block the ability of SHU9119, a synthetic
MC3/4-R antagonist, to antagonize MC4-R signaling. Further-
more, there was no direct interaction of this compound with the
MC4-R, either alone or in the presence of a-MSH. One of these
compounds, TTP2515, was used for the current studies. We
utilized TTP2515 in numerous rodent models to further
investigate the contribution of AgRP to energy balance. We
initially examined the ability of TTP2515 to inhibit the effects of
exogenous icv AgRP administration in the rat. We next
investigated the ability of this compound to inhibit endogenous
AgRP in lean and obese mouse models, including diet-induced
obese (DIO) and leptin-deficient ob/ob mice. As the melanocortin
system is known to mediate adaptive responses observed after
acutely switching mice to a high fat diet (HFD), we investigated the
effects of TTP2515 under these conditions [30]. As AgRP is
markedly upregulated by fasting, we also studied the metabolic
responses to fasting and refeeding [11,13,31]. Finally, we
examined the effects of TTP2515 on the thyroid axis under both
fed and fasted conditions in a number of these experiments. AgRP
KO mice were employed in these various models to determine




All animal experiments were performed at Columbia University
in approved animal facilities in compliance with federal regula-
tions governing the use of animals in research. The animal
facilities at Columbia University are accredited by the Association
for the Assessment and Accreditation of Laboratory Animal Care
and staffed by full time veterinarians (Animal Welfare Number
A3007-01). All studies were in compliance with The National
Research Council’s Guide to the Care and Use of Laboratory
Animals and were approved by the Columbia University
Institutional Animal Care and Use Committee.
Experiments
A streamlined description of all of the experiments is provided
in Table S1.
In vitro. The effect of TTP2515 on AgRP inhibition of the
MC4-R was tested in vitro in HEK293 cells overexpressing the
human MC4-R. The cell line was licensed from the University of
Michigan [32]. The cells were cultured in Gibco Dulbecco’s
Modified Eagle Medium (Life Technologies; Grand Island, NY
USA) medium supplemented with 0.1 mM non essential amino
acids and 10% fetal bovine serum and kept at 37uC in a
humidified atmosphere containing 5% CO2 until they were 65–
80% confluent. On the day of the experiment the cells were
harvested and resuspended to a density of 26106 cells/ml in
Earle’s Balanced Salt Solution (Sigma-Aldrich; St. Louis, MO,
USA, containing 1:10 dilution of anti-cAMP antibody).
206103cells/well were added to 384-well Nunc plates containing
human AgRP 83–132 (20 nM final concentration) and TTP2515 (at
the final assay concentrations depicted in Fig. 1). After 15 minutes
of incubation at 37uC in a humidified atmosphere containing 5%
CO2, the cells were stimulated with a-MSH (12 nM final assay
concentration) and kept under the same incubation conditions for
30 minutes. At the end of the incubation period, cAMP production
was measured using a [FP]2 cAMP fire kit (Perkin-Elmer Cat #
FB A203040KT) according to the manufacturer instructions.
Positive (C+, 20 nM human AgRP83–132 without compound) and
negative (C-, no AgRP and no compound) controls were run in
parallel under the same experimental conditions.
Rats. Male Sprague-Dawley rats weighing 200–250 g were
purchased from Charles River (Wilmington, MA, USA) and used
for all rat experiments. Animals had ad libitum access to water and
LabDietH Rodent Chow 5001 (13.5% fat; PMI Nutrition
International). Rats were acclimatized to a natural light/dark
cycle prior to surgery. In all experiments, rats were anesthetized
with pentobarbital (50 mg/kg) by intraperitoneal (i.p.) injection for
icv cannula placement. In the acute icv injection rat experiment, a
22-gauge stainless steel cannula was inserted stereotaxically into
the right lateral ventricle (coordinates from bregma: lateral
1.3 mm; caudal 0.8 mm; depth from dura 3.5 mm). In the
chronic infusion experiment, a 28-gauge stainless steel cannula
connected by vinyl catheter tubing to a 7-day osmotic pump
(ALZET model 2001, Cupertino, CA, USA) delivering 1 ml/hr of
normal saline was inserted stereotaxically into the right lateral
ventricle (same coordinates as above). Rats were individually
housed and allowed to recover for 5–7 days after cannula
placement. During this recovery period, rats receiving icv
injections were acclimated to restraining to minimize stress during
injections. Before each experiment, rats were divided into
treatment groups of equivalent weight and daily food intake. In
all experiments peptides were dissolved from lyophilized stock in
sterile normal saline immediately before use. Animals exhibiting
signs of illness and whose food consumption fell to less than 10
grams per day were excluded from analyses. Two rats from
Experiment 2a were excluded from day 3 onwards due to illness and
decreased food intake.
Mice. Mice were housed under barrier conditions with a
12:12-hr light-dark cycle. Male C57BL/6 mice from Charles
River Laboratories and C57BL/6J mice and leptin-deficient mice
(Stock #632) from Jackson Laboratories (Bar Harbor, ME, USA)
were utilized in the experiments as indicated. The AgRP knockout
(KO) mouse line was obtained from Dr. Van der Ploeg [21]. Mice
were backcrossed 6 times to a coisogenic C57BL/6J line, the
C57BL/6J-Aw-J/J strain. AgRP KO and WT mice were generated
from homozygous matings and male mice were used in the
experiments as indicated. Ablation of AgRP in the mediobasal
hypothalamus was confirmed by genotyping and via both
qRTPCR for gene expression (F59GCAAAGGCCATGCT-
GACTGC39, R59CTTCTTGAGGCCATTCAGAC39) and via two
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separate assays measuring AgRP (Human AgRP Quantikine
ELISA, R&D Systems, Inc, Minneapolis, MN; and RIA, using
synthetic AgRP83–132 standard and iodinated tracer as described
previously [33]).
Mouse body weight, food intake, and body
composition. All body weight and food intake measurements
were obtained daily from singly housed mice unless otherwise
indicated. Food was measured using either the LabMaster
Calorimetry System feeding baskets or specialized feeding
chambers that fit into traditional homecages. Body composition
measurements were obtained by NMR (Minispec Analyst AD;
Bruker Optics, Silberstreifen, Germany). In all experiments,
baseline body weight, food intake and body composition were
equivalent between groups, unless otherwise indicated.
Mouse diets. The following diets were used for mouse
experiments as indicated: normal chow diet (Lab diet #5053, 13%
kcal from fat), breeder chow diet (Lab diet #5058, 22% kcal from
fat), 45% HFD (Research Diets 12451, 45% kcal from fat), 60%
very HFD (Research Diets 12492, 60% kcal from fat), and 10%
chow diet (Research Diets 12450B, 10% kcal from fat).
Indirect calorimetry. The LabMaster Calorimetry System
(TSE Systems, Bad Homburg, Germany) was used to measure
oxygen consumption (VO2), carbon dioxide production (VCO2)
and activity every 26 minutes (except for Experiment 5, which was
every 14 minutes). Mice were acclimated to the calorimetry system
for a minimum of 24 h prior to starting the experiment. After
acclimation, baseline measurements were obtained for a minimum
of 24 h to appropriately randomize mice. In all experiments,
baseline calorimetry parameters were equivalent between groups.
Approximately 2 h of measurements were excluded during each
dosing session as the mouse was physically removed from the
chamber for gavaging. Relative VO2 and energy expenditure (EE)
were derived by dividing the mean VO2 or EE of a specific time
period (ie-dark cycle) by the total counts of that time period; values
are presented as multiplied by 1000.
Drug compound. In all animal experiments, TTP2515 was
dissolved in sterile water and administered via oral gavage at the
dosage indicated (5–50 mg/kg). The control group received water
at the same volume per kg as the treatment group. Animals were
acclimated to gavaging before experimental treatment was
administered. In the all experiments except Experiment 2a,
TTP2515 was administered twice daily, with doses 10–12 h apart.
Hormone analyses. Blood was collected from the trunk after
decapitation at sacrifice or from the submandibular pouch. Trunk
blood was collected into tubes containing EDTA and plasma was
stored at 280uC. Submandibular blood samples were collected
into tubes at room temperature and serum was stored at 280uC.
Hormones were measured using commercially available RIAs:
Leptin and insulin (EMD Millipore, Billerica, MA, USA) and total
T4, free T4 and total T3 (Coat-A-Count H, Siemens Healthcare
Diagnostics, Tarrytown, NY, USA).
Measurement of hypothalamic mRNA levels. RNA isola-
tion was performed using the RNeasy Lipid Tissue Mini Kit
(Qiagen USA, Valencia, CA) in conjunction with the RNase-Free
DNase set (Qiagen USA). cDNA was synthesized using the
Superscript III First-Strand cDNA Synthesis Kit (Life Technolo-
gies Corporation/Invitrogen, Grand Island, NY) and was analyzed
using quantitative RT-PCR performed with Lightcycler 480
SYBR Green I Master (Roche Applied Science, Indianapolis,
IN) in the Lightcycler 480 Real-Time PCR system (Roche Applied
Science). Samples were normalized to b-actin. Primer sequences:
Mouse: Pomc F59CAGTGCCAGGACCTCACCACGG39 R59
CGGTCCCAGCGGAAGTGACCC39; Agrp F59 GCAAAGGC-
CATGCTGACTGC39 R59 CTTCTTGAGGCCATTCA-





Statistical analysis was performed with Student’s t test when
only two groups were compared. Analysis of variance (ANOVA)
followed by Fisher’s protected least squares difference test was used
when comparing more than two groups. Repeated measures two-
way ANOVA with Bonferroni post-hoc analysis or Dunnett’s
multiple comparison test was used to analyze cumulative food
intake and body weight measurements in multiple groups over
time. P,0.05 was considered statistically significant. Results are
reported as mean values 6 SEM.
Figure 1. Effects of AgRP and TTP2515 on a-MSH-induced cAMP production. (A) a-MSH-induced cAMP production in HEK293 cells
overexpressing human MC4R (green diamond); inhibition of a-MSH(3 nM)-induced cAMP production by increasing amounts of AgRP (pink diamond)
(B) a-MSH-induced cAMP production in HEK293 cells overexpressing human MC4-R in the presence of 20 nM AgRP, 3 nM a-MSH and increasing
concentrations of TTP2515 (red diamond). (C+, cAMP production in the presence of a-MSH (3 nM) and AgRP (20 nM) and in the absence of TTP2515.
C-, cAMP production in the presence of a-MSH (3 nM) no AgRP or TTP2515).
doi:10.1371/journal.pone.0065317.g001
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Experimental Protocols
Experiment 2: Effects of TTP2515 on the orexigenic and
metabolic effects of icv AgRP injection in rats. In Experiment
2a, four groups of rats were studied (n= 5–7/group). Half received
icv human AgRP83–132 (Phoenix Peptides 003–53; Burlingame,
CA, USA) with either oral TTP2515 or water and half received icv
saline with either oral TTP2515 or water. On day 0, between
1730–2030 h, rats received either oral TTP2515 (30 mg/kg) or
water and either 0.2 nmol AgRP or saline icv (delivered in a 5 uL
bolus over the course of one minute). The following day (day 1),
rats received either TTP2515 (30 mg/kg) or water between 1130–
1230 h. On day 2 rats received a final dose of oral TTP2515 or
water and icv AgRP or saline between 1500–1800 h. Measure-
ments were obtained on days 1–4 between 0900–1000 h and rats
were sacrificed on day 4. In Experiment 2b, four groups of rats were
used to study the effects of TTP2515 during chronic icv AgRP
infusion (n = 7–8/group). On day 0, icv pumps infusing saline were
exchanged for new pumps delivering either saline or 0.64 nmol/
day human AgRP83–132. The first oral dose of water or TTP2515
(30 mg/kg) was administered shortly after the pump exchange,
and water or TTP2515 continued to be administered twice daily
between 800–1000 h and 1800–2000 h. Rats were sacrificed on
day 8. Trunk blood was collected for hormone assays, a 3-mm
mediobasal hypothalamic section was dissected for mRNA
analysis, and adipose and liver weight were quantified.
Experiment 3: Effects of TTP2515 on metabolic
parameters in DIO mice. In Experiment 3a, 8-week old
C57BL/6 mice received a 45% HFD for 16 weeks at which time
mean body weight increased from 21.160.3 g to 39.461.0 g.
Mice were randomized to receive either water or TTP2515
(30 mg/kg) by oral gavage twice daily for 21 days (n = 7–8/group).
Body weight and food intake were monitored approximately every
3 days. On day 15, blood was obtained after a 6 h fast. Body
composition was assessed before treatment and on day 20 of
treatment. Mice received the last dose of TTP2515 or water at
0800 h on day 21 and were sacrificed 6 h later. At sacrifice, blood
was collected for hormone analyses, a 3-mm mediobasal
hypothalamic section was dissected for mRNA analysis, and liver
weight was quantified. In Experiment 3b, 6-week old C57BL/6J
mice received a 45% HFD for 15 weeks during which time mean
body weight increased from 21.560.3 g to 34.660.5 g. Mice were
acclimatized to calorimetry chambers and received treatment of
either TTP2515 (30 mg/kg) or water twice daily starting during
the dark cycle and continuing for 3.5 days (n = 8/group).
Experiment 4: Effects of TTP2515 on metabolic
parameters in leptin-deficient mice. 9-week old leptin-
deficient ob/ob mice maintained on a normal chow diet were
randomized to receive water or TTP2515 twice daily at increasing
doses (Days 1–4, 5 mg/kg; Days 5–7, 15 mg/kg; Days 8–10,
30 mg/kg; Days 11–25, 50 mg/kg) for a total of 25 days (n = 7/
group). Mice were placed in calorimetry chambers during days 1–
14. Mice were fasted before the evening of day 13 and food intake
was measured during refeeding the next morning. A second fast
was performed before the evening of day 19 for an i.p. glucose
tolerance test (GTT). Body composition was assessed before
treatment and on day 24 of treatment. Mice received the last dose
of TTP2515 or water on day 24 at 2200 h and were sacrificed at
1100 h on day 25. At sacrifice, blood was collected for hormone
analyses and liver weight was quantified.
Experiment 5: Effects of TTP2515 on metabolic
parameters in fed and fasted lean BL6 mice. 16-week old
C57BL6/J mice on a breeder chow diet were administered either
TTP2515 (30 mg/kg) or water twice daily in calorimetry
chambers (n = 8/group). Mice were fed on days 1–3 and then
fasted. Mice received the last dose of TTP2515 or water at 2100 h
on day 3 and were sacrificed at 0800 h on day 5 and blood was
collected for hormone analyses.
Experiment 6: Effects of TTP2515 on metabolic
parameters in AgRP KO and WT mice on a 45% fat diet
and calorimetry parameters in AgRP KO mice. In Exper-
iment 6a, 20-week old AgRP KO and WT mice maintained on
breeder chow were switched to a 45% HFD (n= 6–7/group). The
next day (24 h later, referred to as day 1) mice started treatment
with either water or TTP2515 (30 mg/kg) in the AgRP KO
groups or TTP2515 in the WT group, twice daily for 20 days.
Body composition was assessed before treatment and on day 19 of
treatment. Mice received the last dose of TTP2515 or water on
day 20 at 0900 h and mice were sacrificed 6 h later, and blood
was collected for hormone analyses. In Experiment 6b, 5–7 month
old AgRP KO mice maintained on a breeder chow diet received
either TTP2515 at increasing doses (Days 1–7, 30 mg and Days 7–
10, 50 mg/kg) or water for 10 days in calorimetry chambers
(n = 8/group).
Experiment 7: Effects of TTP2515 on hyperphagia and
metabolic parameters after an acute switch to a very high
fat diet in C57BL6/J mice and AgRP KO mice. In Experiment
7a, 14-week old C57BL6/J mice maintained on a breeder chow
diet were switched to a 60% very HFD and simultaneously started
treatment with either TTP2515 (30 mg/kg) or water twice daily
for 5 days (n = 8/group). Body composition was assessed on day 4
of treatment. Mice received their last dose of TTP2515 or water at
0800 h on day 6 and were sacrificed 4 h later. At sacrifice, blood
was collected for hormone analyses and a 3-mm mediobasal
hypothalamic section was dissected for mRNA analysis. In
Experiment 7b, 6–7 month old AgRP KO mice maintained on a
10% chow diet were switched to a 60% very HFD and
simultaneously started treatment with either TTP2515 (5, 15 or
30 mg/kg) or water for 7 days (n = 7/group). Body composition
was assessed at baseline and on day 4 of treatment. On the evening
of day 4, mice received TTP2515 or water at 2000 h. On day 5,
submandibular pouch blood was collected at 1100 h and mice
continued to receive TTP2515 or water twice daily with the last
dose at 2200 h on day 6. Mice were fasted starting at 2100 h on
day 5 and blood was collected at 0800 h on day 7.
Experiment 8: Effects of TTP2515 on refeeding and T4
after fasting in AgRP KO and WT mice. In Experiment 8a, 5–7
month old AgRP KO and WT mice (n = 7–8/group) maintained
on a normal chow diet were utilized in three separate fasting and
refeeding experiments. In all experiments, both AgRP KO and
WT mice were fasted for 24 h and then started treatment with
either TTP2515 (10, 25, or 50 mg/kg) or water. Mice were refed
1 h after the first dose. Food intake and body weight measure-
ments were obtained at the 3, 9, and 20 h timepoints and a second
dose of TTP2515 or water was administered at the 9 h timepoint.
In Experiment 8b, 3–4 month old AgRP KO and WT mice
maintained on normal chow diet were utilized in this experiment
(n = 7–9/group) to measure T4 levels after fasting. Before
intervention, submandibular pouch blood was collected for
baseline values. After recovery, mice were fasted and received 3
doses of TTP2515 or water at 2100 h on day 1, and at 0900 and
2000 h on day 2 and another blood sample was obtained at
0700 h on day 3.
Results
Experiment 1: Effects of TTP2515 in vitro
HEK293 cells overexpressing the human MC4-R were used to
study the effects of TTP2515 on AgRP inhibition of a-MSH-
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induced cAMP production. As expected, a-MSH increased cAMP
production and AgRP inhibited a-MSH-induced cAMP produc-
tion by competing with a-MSH for binding to the MC4-R
(Fig. 1A). TTP2515 blocked AgRP inhibition of a-MSH-induced
MC4-R activation; with TTP2515 a-MSH was able to activate the
MC4-R even in the presence of AgRP (Fig. 1B). Furthermore,
TTP2515 had no effect on cAMP levels in HEK293 cells
expressing MC4-R in the absence of AgRP, either with or without
sub-maximal concentrations of a-MSH (results not shown).
Experiment 2: Effects of TTP2515 on the Orexigenic and
Metabolic Effects of icv AgRP Injection in Rats
Experiment 2a. Rats received either a single icv injection of
AgRP or saline on days 0 and 2, and a single oral gavage of
TTP2515 (30 mg/kg) or water on days 0, 1 and 2. Overall during
days 1–2, concomitant treatment with TTP2515 significantly
attenuated AgRP-induced increases in food intake and body
weight (p,0.05, Fig. 2A,B ). On day 3, food intake and body
weight gain were significantly increased in the AgRP+Water group
(p,0.05), and these increases tended to be attenuated in the
AgRP+TTP2515 group (p = 0.06 vs AgRP+Water) so that this
group was not different from saline. No significant differences
between the Saline+Water and Saline+TTP2515 groups were
observed during the entire experiment.
Experiment 2b. Rats were continuously infused icv for 8
days with either AgRP or saline and also received twice daily oral
gavage with either TTP2515 (30 mg/kg) or water. AgRP
significantly stimulated food intake and body weight gain during
the entire experiment (p,0.05). Overall, AgRP-induced increases
in food intake and body weight gain were partly reversed in the
AgRP+TTP2515 group (p = 0.01, Fig. 2C,D). At sacrifice, liver
weight (Table 1) and fat pad mass (Fig. 2E) were significantly
increased in rats receiving AgRP (p,0.0001), however these
increases were attenuated in the AgRP+TTP2515 group (p,0.05
vs AgRP+Water). Total T4 levels were significantly suppressed by
AgRP+Water treatment (p,0.01 vs Saline+Water, Fig. 2F) and
this was reversed in the AgRP+TTP2515 group (p,0.05). Free T4
levels tended to be suppressed in the AgRP+Water group (p= 0.08
vs Saline+Water, Fig. 2G) and this was reversed in the
AgRP+TTP2515 group (p,0.01). No differences in total T3
levels were detected (Table 1). Leptin and insulin levels were
significantly elevated in both groups receiving icv AgRP, and
concomitant TTP2515 treatment tended to decrease levels of these
hormones, however this did not reach significance (Table 1).
Hypothalamic Agrp and Pomc mRNA levels were measured at
sacrifice and no significant effect of TTP2515 on gene expression
was noted (results not shown).
Experiment 3: Effects of TTP2515 on Metabolic
Parameters in DIO Mice
Experiment 3a. DIO mice were gavaged with TTP2515
(30 mg/kg) or water twice daily for 21 days. Cumulative food
intake and body weight gain were significantly decreased
compared to water-treated mice (Fig. 3A,B). On day 20, the
TTP2515-treated mice had significantly reduced percent fat mass
compared to water treated mice (p,0.05, Fig. 3C), lost a greater
amount of fat during treatment vs. the water group (22.660.4 g
vs 20.560.2 g, p,0.001), and tended to have lower absolute fat
grams after treatment (12.060.9 g vs 9.860.8 g, p = 0.08). No
difference in lean mass was observed between groups after
treatment (Table 2). Mice received their last dose of TTP2515
or water at 800 h on day 21 and were sacrificed 6 h later. Insulin
levels tended to be lower in TTP2515 treated mice after a 6 h fast
on day 15 of the study (p = 0.14) and both insulin (p = 0.13) and
leptin levels (p = 0.13) at sacrifice tended to be lower in TTP2515
treated mice (Table 2). At sacrifice, total T4, but not T3, levels
were significantly elevated by TTP2515 treatment (p,.0001,
Fig. 3D,E). No significant difference in Pomc or AgrpmRNA in the
mediobasal hypothalamus was detected.
Experiment 3b. A separate group of DIO mice were placed
in the calorimetry system and received either TTP2515 (30 mg/
kg) or water for 3.5 days. Cumulative food intake (10.560.5 g vs
10.060.6 g) and body weight change (20.160.2 g vs
20.560.4 g, Water vs TTP2515) were not significantly different
in DIO mice receiving TTP2515 treatment for 3.5 days. During
the first two nights of treatment, VO2, EE and physical activity
were reduced in TTP2515-treated mice compared to the water-
treated mice. On the first night, this was only a tendency (Table
3), however this effect was significant during the night of day 2
(Table 3, Fig. 3F, G). Yet, these effects were transient, as VO2,
EE and activity were not different during the nights of days 3 and
4 (Table 3). Furthermore, as the observed decrease in VO2 and
EE was likely driven by decreased activity, VO2 and EE were
divided by activity to produce a ‘‘relative’’ value. Relative VO2
and EE were significantly higher in TTP2515 treated mice during
the dark cycle on day 1 (VO2:374.2654.4 vs 231.2622.6 ml/hr/
kg per counts; EE: 2.160.3 vs 1.360.1 W kg21 per counts,
p,0.05) and day 2 (VO2:428.168.3 vs 227.0622.2 ml/hr/kg per
counts; EE: 2.460.5 vs. 1.360.1 W kg21 per counts, p,0.05) but
not different between groups on days 3 and 4. Respiratory
quotient (RQ) was not different during days 1–2, however during
the light cycle of day 3, mean RQ tended to be lower in TTP2515
treated mice compared to the water group (p,0.08), and was
significantly lower during the first half of the light cycle (p,0.05,
Fig. 3H).
Experiment 4: Effects of TTP2515 on Metabolic
Parameters in Leptin-deficient Mice
Leptin-deficient ob/ob mice maintained on a normal chow diet
received either TTP2515 at increasing doses (5–50 mg/kg) or
water treatment for 25 days. During days 1–13, mice were placed
in the calorimetry system. In ob/ob mice, average daily food intake
was decreased with 15 mg (p = 0.06), 30 mg/kg (p,0.05) and
50 mg/kg (p,0.01) TTP2515 treatment (Fig. 4A); significant
reductions in body weight were observed at the 50 mg/kg dose
(p,0.05, Fig. 4C). No effects on VO2, EE or activity were
observed during any of the dosing periods except transiently at the
15 mg/kg dose, where mean VO2 and mean EE (p,0.05) were
decreased during the dark cycle of day 6, with a trend for
decreased activity (p = 0.10, Table 3). However, this decrease in
VO2 and EE was not evident if adjusted for activity. Mean RQ
was significantly lower in 50 mg/kg TTP2515 treated mice,
however this was not noted at lower doses. The decrease in RQ
was observed during the light cycle immediately upon starting the
50 mg/kg treatment on day 11 and was again noted on day 12
(Fig. 4D).
Mice were fasted during the evening of day 13. Fasting did not
significantly increase activity in water treated mice, however
TTP2515 treatment during fasting decreased activity (p,0.01),
VO2 and EE (p= 0.05) compared to water treatment (Table 3). If
adjusted for activity, VO2 and EE were increased in the TTP2515
group (p,0.05). TTP2515 treated mice also lost significantly less
weight during the fast vs. water treated mice (Water 22.360.1 vs.
TTP2515 21.560.2 g, p,0.01), which may be secondary to the
decreased activity observed. Mice were refed the next morning in
homecages outside the calorimetry system. Both groups refed to a
similar degree at 22 h (Water 4.060.5 vs TTP2515 3.060.5 g,
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Figure 2. Effects of TTP2515 on body weight and food intake in rats receiving icv AgRP. (A–B) Rats received a single icv injection of
0.2 nmol AgRP or saline on days 0 and 2 and received 30 mg/kg TTP2515 or water via oral gavage once per day during days 0–2. (A,B) AgRP+Water
increased food intake and body weight gain; this was partly reversed in the AgRP+TTP2515 group. (C–G) In a separate experiment, rats were
continuously infused icv with either 0.64 nmol/day AgRP or saline and gavaged twice daily with either water or TTP2515 at 30 mg/kg. (C,D) AgRP
significantly increased food intake and body weight gain during the entire treatment period. The AgRP-induced increases in food intake and body
weight gain were significantly attenuated by TTP2515. (E) Fat pad mass increased with AgRP and was attenuated by TTP2515. (F) Total T4 levels were
significantly suppressed in the AgRP+Water group and this suppression was almost entirely reversed in the AgRP+TTP2515 group. (G) Free T4 levels
tended to be suppressed in the AgRP+Water group (p = .08 vs Saline+Water) and this suppression was reversed in the AgRP+TTP2515 group. *p,.05
vs Saline+Water; +p,.05 AgRP+Water vs AgRP+TTP2515.
doi:10.1371/journal.pone.0065317.g002
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p= 0.17) and gained a similar percentage of their original body
weight during refeeding (Water 42.863.4% vs TTP2515
25.6615.9%, p= 0.31).
On day 21, mice were fasted overnight and a GTT performed
the next morning revealed no difference in glucose tolerance
between groups (data not shown). MRI performed on day 24
showed that TTP2515 treated mice had significantly lower fat
mass compared to water treated mice (p,0.001, Fig. 4B); lean
mass was not different between groups. Mice received their last
dose of TTP2515 or water on day 24 at 2200 h and were
sacrificed at 1100 h on day 25. At sacrifice, liver weight (p,0.05)
was significantly reduced in TTP2515 treated mice (Table 2),
however plasma glucose, insulin, body temperature (Table 2) and
total T4 levels (Fig. 4E) were not different between groups.
Experiment 5: Effects of TTP2515 on Metabolic
Parameters in Fed and Fasted Lean BL6 Mice
Lean mice on a breeder chow diet were treated with either
TTP2515 (30 mg/kg) or water for a total of 4 days in the
calorimetry system. Mice were fed ad lib and then fasted. In fed
mice, TTP2515 treatment did not decrease daily food intake
(Water 3.060.0 vs. TTP2515 3.160.2 g) or attenuate weight gain,
and weight loss was similar between groups during fasting
(Fig. 5A). No significant differences in VO2 or EE were noted
during days 1 and 2. However, a small but significant decrease in
activity in TTP2515 treated mice was noted during the dark cycle
on day 1 (p,0.05); this effect was transient as it was no longer
observed during the dark cycle of day 2 (Table 3). Although no
differences in RQ were observed during the dark cycle, on day 3
mean RQ was significantly lower during the light cycle in
TTP2515 mice (p,0.05, Fig. 5B). As mice were fasted from the
evening of day 3, it is unknown if this reduction in RQ would
persist. During fasting, a significant increase in activity was noted
in the control water mice during the dark cycle that was not
observed in TTP2515 mice. Activity in the water group during
fasting was elevated versus the fed state (day 2) as well as compared
to TTP2515 mice during fasting on day 4 (p,0.05, Fig. 5C, D).
No difference in VO2 or EE was observed between the TTP2515
and water groups during fasting (Table 3). Total T4 and T3 levels
were similar before treatment in these two groups of mice that
were subsequently treated with TTP2515 or water and fasted.
After fasting, total T4 and T3 levels were significantly suppressed
in both groups. However, after fasting, T4 levels were significantly
higher in TTP2515 compared to water treated mice, while total
T3 levels were similar between groups (p,0.05, Fig. 5E, F).
To further investigate if TTP2515 modulates metabolic
parameters in lean mice, we conducted a separate experiment in
which 50 mg/kg TTP2515 or water was administered twice daily
via oral gavage to lean, breeder-chow fed WT mice (n = 7/group)
for 7 days. During this time daily and cumulative food intake (WT
21.860.6 vs. TTP2515 21.160.4 g, p= 0.59) and daily and
cumulative body weight gain (Water 20.460.2 vs. TTP2515
20.260.3 g, p= 0.62) were similar between groups and both
groups had similar fat and lean mass after 7 days of treatment
(data not shown). The last dose of TTP2515 or water was
administered at 2000 h on day 6 and a blood sample obtained at
0900 h on day 7 revealed a significant increase in total T4 levels in
the TTP2515 group compared to the water group (5.360.2 vs.
4.360.2 mg/dl, p,0.01).
These experiments demonstrate that TTP2515 does not reduce
food intake or body weight gain in lean, chow-fed mice at doses up
to 50 mg/kg. However, chronic TTP2515 treatment did increase
total T4 levels in both fasted and fed lean mice. We also observed
that TTP2515 can transiently suppress physical activity and
prevent fasting-induced increases in physical activity.
Table 1. Effects of TTP2515 on hormone levels and liver weight in rats receiving icv AgRP infusion.
Saline+Water AgRP+Water AgRP+TTP2515 Saline+TTP2515
Leptin (ng/ml) 2.760.4 21.960.8* 18.564.2* 2.360.3
Insulin (ng/ml) 2.760.6 12.662.0* 9.762.2* 1.660.3
Plasma Glucose (mg/dl) 162.164.5 17067.0 159.368.0 150.664.5
Liver Weight (g) 14.160.7 25.061.1* 21.861.7*{ 13.760.5
Total T3 (ng/dl) 49.463.2 40.564.0 40.164.6 44.764.5




Table 2. Effects of TTP2515 in DIO and leptin-deficient mice.
Water TTP2515
Exp 3a: DIO mice
Lean Mass (Day 20) (g) 19.860.4 19.960.6
Glucose-Day 15 (ng/dl) 161.064.4 164.063.9
Insulin-Day 15 (ng/ml) 2.460.5 1.660.2
Insulin (ng/ml) 2.060.3 2.160.7
Leptin (ng/ml) 25.062.6 23.363.8
Liver Weight (g) 1.360.1 1.360.1
Liver Weight as a % of Body Weight (%) 3.560.1 3.860.1
Exp 4: Leptin-deficient mice
Glucose (ng/dl) 452.9634.6 479.7634.5
Insulin (ng/ml) 6.161.3 6.660.7
Liver weight (g) 2.960.1 2.360.2*
Liver Weight as a % of Body Weight (%) 5.760.2 5.360.3
Body Temperature (uC) 32.860.3 32.660.2
All measurements reported at sacrifice in ad lib fed mice unless otherwise
indicated.
Values are mean 6 SE.
*p,0.05 vs water.
doi:10.1371/journal.pone.0065317.t002
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Experiment 6: Effects of TTP2515 on Metabolic
Parameters in AgRP KO and WT Mice on a 45% Fat Diet
and Calorimetry Parameters in AgRP KO Mice
Experiment 6a. AgRP KO mice were treated with either
TTP2515 (30 mg/kg) or water and WT mice received TTP2515
(30 mg/kg) for a total of 19 days while receiving a 45% HFD. At
the start of the experiment, AgRP KO TTP2515 (28.860.5 g) and
AgRP KO water (29.360.6 g) groups weighed significantly less
than the WT TTP2515 group (32.361.2 g); however, baseline
food intake was similar between groups. Overall during the entire
experiment, there was no significant difference in food intake
between groups. Since the peak effect was observed during the first
four days of treatment, cumulative food intake was analyzed
during this period and was found to be significantly lower in the
WT TTP2515 and the KO TTP2515 group, compared to the KO
water group during days 2–4 (p,0.05, Fig. 6A). Overall, there
was a significant suppressive effect of treatment on cumulative
weight change between the groups (p = 0.01, Figure 6C). Post-
hoc analysis revealed that body weight gain was more frequently
significantly lower in the WT TTP2515 group vs. the KO water
group, rather than in the KO TTP2515 group vs. the KO water
group. By day 19 of the experiment, the cumulative weight loss in
the WT TTP2515 group was 21.3560.40 g vs. a gain of
0.3460.59 g in the KO water group, while the KO TTP2515
group lost 20.9560.52 g. After treatment, the WT TTP2515
group gained significantly less fat compared to the KO water
Figure 3. Effects of TTP2515 on metabolic and calorimetry parameters in DIO mice. (A–E) DIO mice (16 weeks on 45% fat diet) received
TTP2515 (30 mg/kg) or water twice daily via oral gavage. (A,B) TTP2515 treatment significantly decreased food intake and body weight gain. (C)
Percent fat mass was significantly lower in TTP2515 treated mice at the end of the study. (D) TTP2515 treated mice had elevated total T4 levels. (E)
Total T3 levels were similar between groups. (F–H) In a separate experiment DIO mice (45% fat diet for 15 weeks) received TTP2515 (30 mg/kg) or
water twice daily via oral gavage. (F,G) Mean oxygen consumption and total activity were significantly decreased during the dark cycle of day 2 in
TTP2515 treated mice. (H) Mean respiratory quotient was significantly decreased during the first half of the light cycle of day 3 in TTP2515 treated
mice. **p,0.0001, *p,0.05 vs. water.
doi:10.1371/journal.pone.0065317.g003
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group (p,0.05), while the KO TTP2515 group did not (p = 0.12,
Fig. 6B). Lean mass was similar between all groups after
treatment. At sacrifice, both total and free T4 levels were higher
in WT and KO TTP2515 treated mice compared to KO water
treated mice (p,0.05, Fig. 6D, E).
Experiment 6b. Lean AgRP KO mice maintained on a
breeder chow diet were administered either TTP2515 (30 mg/kg
days 1–7, 50 mg/kg days 7–10) or water in the calorimetry system.
During the 30 mg/kg treatment period, no significant effects on
average daily food intake (Water 3.260.2 vs TTP2515 2.960.1 g)
or body weight were observed (Water 27.260.8 vs TTP2515
26.660.5 g). During the 30 mg/kg dosing period, RQ was
transiently lower during the dark cycle on days 1 and 2
(p,0.05, data not shown) in the TTP2515 group and was not
different during any other point in the experiment (Fig. 6H). On
day 3, VO2, EE and activity were transiently lower in TTP2515
treated mice during the dark cycle (p,0.05, Fig. 6F, G; Table
3); this is similar to what has been observed in lean, DIO and ob/ob
mice in Exp 3–5. Subsequently a tendency for reduced activity
persisted without any change in VO2 or EE (Table 3).
Adjustment for activity showed that relative VO2 and EE were
equivalent between groups during the dark cycles. No other
differences in calorimetry parameters were observed during the
30 mg/kg treatment period. During the 50 mg/kg treatment
period, average daily food intake was similar between groups
(Water 3.060.1 vs. TTP2515 2.860.1 g, p= 0.30) and body
weight was not different (Water 27.360.9 vs. 26.560.5, p = 0.40),
although the TTP2515 treated group tended to gain less weight by
day 10 (Water 0.260.2 vs. TTP2515 20.460.2 g, p = 0.05). At
the 50 mg/kg dose, there were no significant differences in any
calorimetry parameters but activity tended to be lower in
TTP2515 treated mice during the dark cycle on days 8–10,
without any change in VO2 or EE (Table 3). If adjusted for
activity, relative VO2 and EE were either not significantly
different or tended to be higher in the TTP2515 group vs. water
on these days (Day 8 p,0.05, Day 9 p=0.05, Day 10 p= 0.32).
Experiment 7: Effects of TTP2515 on Hyperphagia and
Metabolic Parameters After an Acute Switch to a Very
High Fat Diet in C57BL6/J Mice and AgRP KO Mice
Experiment 7a. Lean, BL6 mice maintained on breeder
chow were all switched to a 60% fat diet and simultaneously
started treatment with either TTP2515 (30 mg/kg) or water. After
switching to a HFD, water treated mice increased their caloric
intake (p,0.0001, baseline vs. day 1) while the TTP2515 treated
mice actually decreased their caloric intake (p,0.05, baseline vs.
day 1). Furthermore, daily food was significantly lower in
TTP2515 compared to water treated mice during days 1–2
(p,0.0001), however by day 3 daily food intake was similar
between groups. Cumulative caloric intake was significantly lower
in TTP2515 vs. water treated mice during the entire treatment
period (p,0.0001, Fig. 7A). Water treated mice gained weight
after switching to the higher fat diet; oppositely, TTP2515 treated
mice lost weight (p,0.01, Fig. 7B). A body composition
measurement on day 4 revealed that TTP2515 treated mice had
significantly lower fat mass compared to water treated mice
(p,0.0001, Fig. 7C), while lean mass was equivalent between
groups (Water 19.660.5 vs. TTP2515 19.760.4 g). At sacrifice,
leptin (p = 0.12) and insulin levels were not significantly different
between groups, however total T4 levels were higher (p,0.0001)
in TTP2515 treated mice (Fig. 7D–F). No significant difference in
Agrp mRNA in the mediobasal hypothalamus was detected.
Table 3. VO2, EE and activity during the dark cycle in calorimetry experiments.
Average VO2 (ml/kg/hr) Average EE (W kg21) Locomotor activity (total counts)
Exp 3b: DIO mice Water TTP2515 Water TTP2515 Water TTP2515
Day 1: Dark Cycle 32776112 3096680 18.360.6 17.360.5 1546261952 1009461858
Day 2: Dark Cycle 33356103 2992692* 18.660.6 16.760.5* 1574661571 964662366*
Day 3: Dark Cycle 31706119 3058681 17.760.7 17.160.5 1377361541 1271062671
Day 4: Dark Cycle 3208689 32326119 17.960.5 18.060.7 1356161924 1218162593
Exp 4: Leptin-deficient mice
Day 6 Dark Cycle 22916110 2007668* 13.260.6 11.560.4* 42716620 28096539
Day 12 Dark Cycle 2072651 1924674 11.860.3 11.060.4 45176964 30296413
Day 13 Dark Cycle (Fasting) 1406636 1262657 7.760.2 6.960.3 53286916 18526298**
Exp 5: Fed/fasted lean BL6 mice
Day 1 Dark Cycle 2963663 2824646 17.160.4 16.360.3 1062561772 62496811*
Day 2 Dark Cycle 2979672 2894628 17.160.4 16.760.2 859261264 72236983
Day 3 Dark Cycle (Fasting) 24406106 2420652 13.560.6 13.360.3 1908664939 1066462218
Day 4 Dark Cycle (Fasting) 25896108 2450644 14.360.6 13.560.3 2219665323 941061773*
Exp 6b: AgRP KO mice
Day 3 Dark Cycle 32326127 2936650* 18.760.8 16.960.3* 1833164147 813761410*
Day 6 Dark Cycle 31116134 2961683 18.060.8 17.160.5 2075666871 776961131
Day 9 Dark Cycle 30696119 2913663 17.760.7 16.860.4 2140467107 820961377
In all VO2 and EE measurements above, adjustment for activity rendered VO2 and EE either significantly higher in the TTP2515 group or equivalent between groups. W,
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Figure 4. Effects of TTP2515 on metabolic and calorimetry parameters in leptin-deficient mice. Leptin-deficient mice received either
TTP2515 at increasing doses (5–50 mg/kg) or water twice daily via oral gavage. (A) Food intake tended to be lower in TTP2515 treated mice during
the 15 mg/kg treatment period and was significantly lower during the 30 and 50 mg/kg treatment periods. (B) Fat mass was significantly decreased
after 24 days of TTP2515 treatment, while lean mass was not different between groups. (C) Body weight was significantly lower in TTP2515-treated
mice on the 50 mg/kg dose. (D) Immediately upon starting the 50 mg/kg dose, mean respiratory quotient was significantly decreased in TTP2515
treated mice during the light cycle. (E) Total T4 levels at sacrifice were unchanged between groups. +p= 0.06, *p,0.05, **p,0.01 vs water.
doi:10.1371/journal.pone.0065317.g004
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Experiment 7b. AgRP KO mice were all switched from a
10% fat chow diet to a 60% very HFD and simultaneously started
treatment with either water or TTP2515 at 5, 15, or 30 mg/kg
doses. On day 1, after switching AgRP KO mice to the HFD, the
water group’s daily caloric intake increased slightly, although not
significantly. In contrast, the 30 mg/kg TTP2515 treatment group
consumed significantly fewer calories vs. baseline (p,0.001 vs.
baseline values). On day 1, the 15 mg/kg and 30 mg/kg TTP2515
groups dose-dependently consumed fewer calories than the water
group (p,0.05 water vs. both 15 and 30 mg/kg groups, p,0.05
15 mg/kg vs 30 mg/kg dose). Daily caloric intake was also
significantly lower on days 2 and 3 in the 15 and 30 mg/kg groups
(p,0.01) vs. saline. Cumulative food intake is depicted in Fig. 7G;
post-hoc analyses revealed that cumulative food intake was
significantly lower in the 30 mg/kg and 15 mg/kg TTP2515
groups compared to the water group from day 2 and 3 onwards,
respectively (p,0.05). Cumulatively, water treated mice gained
weight after switching to the higher fat diet; oppositely, TTP2515
treated mice lost weight (p,0.01, Fig. 7I). MRI on day 5 revealed
that fat mass was significantly lower in the 15 and 30 mg/kg
groups compared to the water treated group (p,.01, Fig. 7H).
Lean mass was similar between groups (data not shown). After 5
days of treatment, total T4 levels were not different between
groups; however fasting with treatment revealed a significant and
dose-dependent increase in total T4 levels in TTP2515 treated
mice (Fig. 7J).
These experiments indicate the TTP2515 treatment yielded a
potent, anorexic effect in both AgRP KO and WT mice when
switched to a HFD. The anorexic effect persisted for approxi-
mately 2–3 days, after which daily food intake was equivalent
between the TTP2515 and water groups. However, cumulative
food intake and weight gain continued to be lower in TTP2515
compared to water treated mice.
Experiment 8: Effects of TTP2515 on Refeeding and T4
After Fasting in AgRP KO and WT Mice
Experiment 8a. In three separate experiments, mice were
fasted for 24 h and received a single dose of TTP2515 (10, 25, or
50 mg/kg) or water the next morning and were refed 1 h later.
Food intake and body weight measurements were obtained at 3, 9
and 20 h after refeeding and a second dose of TTP2515 or water
was administered at the 9 h timepoint. In all experiments, baseline
food intake was similar between groups, however WT mice were
approximately 3 g heavier than AgRP KO mice (p,0.001). The
10 mg/kg dose did not attenuate refeeding or body weight gain in
either KO or WT TTP2515 treated mice compared to their
respective water counterparts at any of the timepoints measured
(Fig. 8A, B). At the 25 mg/kg dose, there was an overall
significant reduction in food intake (p,0.05) and body weight gain
(p,0.01) in the WT TTP2515 group compared to the WT water
group, however this was not observed between the KO TTP2515
and KO water group. At the 9 h timepoint WT TTP2515 treated
mice gained less weight than WT water treated mice (p,0.01,
Fig. 8C, D), but no difference between KO water and KO
TTP2515 treated mice was observed. At the 20 h timepoint, WT
TTP2515 mice refed less (p,0.01) and gained less weight
Figure 5. Effects of TTP2515 on metabolic and calorimetry parameters in lean fed and fasted mice. Lean, chow-fed mice received either
TTP2515 (30 mg/kg) or water twice daily via oral gavage during both ad lib feeding and fasting. (A) Body weight was not different between groups
during either the fed or fasted periods. (B) During the light cycle of day 3, mean RQ was significantly suppressed in TTP2515 treated mice. (C) During
fasting, total activity was elevated in water treated, but not TTP2515-treated mice. (D) During the second night of fasting, total activity was
significantly lower in TTP2515 treated mice compared to the water group. (E) After fasting, total T4 levels were significantly suppressed in both
groups, however total T4 levels were significantly higher in TTP2515 treated mice. (F) Total T3 levels were suppressed by fasting and fasted levels
were similar between TTP2515 and water treated mice. +p= 0.06, #p,0.05 vs day 2 Dark Cycle (fed); *p,0.05 vs water, a p,0.05 vs respective fed
treatment.
doi:10.1371/journal.pone.0065317.g005
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(p,0.05) than WT water treated mice, however this effect was not
observed between the KO water and KO TTP2515 groups. At the
50 mg/kg dose, there was a significant overall effect of TTP2515
treatment on feeding in both the WT (p,0.01) and KO (p,0.05)
groups compared to their water controls (Fig. 8E). Post-hoc
analyses showed that at the 20 h timepoint, both WT (p,0.0001)
and KO (p,0.01) TTP2515-treated mice refed significantly less
than their water controls. With respect to weight gain, only final
cumulative weight gain at 20 h was significantly less in the WT
TTP2515 vs WT water group; this difference was not significant
between the two KO groups (Fig. 8F).
Thus the 25 mg/kg TTP2515 dose attenuated refeeding and
weight gain specifically in WT, but not AgRP KO mice. At the
50 mg/kg dose, TTP2515 treatment attenuated refeeding in both
AgRP KO and WT mice, suggesting that this higher dose may
elicit non-specific effects.
Experiment 8b. AgRP KO and WT mice were fasted and
received either TTP2515 at 50 mg/kg or water during the fast.
Three doses of TTP2515 were administered with the last dose at
Figure 6. Effects of TTP2515 on metabolic and calorimetry parameters in AgRP KO and WT mice on a 45% high fat diet (A–F) AgRP
KO and WT mice received TTP2515 (30 mg/kg) and AgRP KO mice received water twice daily via oral gavage; all groups were on a 45% fat diet. (A)
During days 1–4, there was an overall suppressive effect of TTP2515 treatment on food intake (p,0.05). Food intake was lower on days 2–4 in the WT
TTP2515 and KO TTP2515 groups compared to the KO water group (p,0.05) (B) WT TTP2515 mice gained significantly less fat mass during treatment
vs. the KO water group, however, this was not true for the KO TTP2515 group (p = 0.12). (C) Overall, there was a significant suppressive effect of
treatment on cumulative body weight change (p = 0.01); body weight gain was more frequently significantly lower in the WT TTP2515 vs. the KO
water group, rather than in the KO TTP2515 vs. the KO water group (D,E) Total and free T4 levels were elevated in both TTP2515 treatment groups
compared to the KO water group. (F–H) AgRP KO mice were administered either TTP2515 (30 mg/kg days 1–7; 50 mg/kg days 7–10) or water twice
daily. (F,G) On day 3 during the dark cycle, oxygen consumption and activity were significantly lower in TTP2515–treated mice. (H) RQ was not
different between groups during the light or dark cycle at the 50 mg/kg dose (showing day 10, representative graph of this timeperiod). +p,0.05 KO
Water vs KO TTP2515; *p,0.05 KO Water vs WT TTP2515; #p,0.05 vs water.
doi:10.1371/journal.pone.0065317.g006
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2000 h; blood samples were collected at 0700 h the next day.
Baseline total T4 levels before fasting and treatment were not
significantly different between groups. After fasting and TTP2515
treatment, total T4 levels were not significantly different between
groups (Fig. 8G).
Discussion
This study shows that TTP2515 functions in vitro as an AgRP
inhibitor, and when administered orally in rats, was able to
attenuate the effects of centrally infused AgRP. When studied in
cells overexpressing the human MC4-R, TTP2515 blocked AgRP-
mediated antagonism of a-MSH-induced increases in cAMP
levels. TTP2515 did not affect the MC4-R either alone or in the
presence of a-MSH, consistent with an interaction with AgRP and
not directly with the MC4-R. Prior studies with a related
compound failed to block SHU9119’s antagonistic effects,
demonstrating selectivity for AgRP. When administered to rats
by oral gavage, TTP2515 blocked AgRP-induced increases in food
intake, weight gain and adiposity, as well as suppression of total T4
levels. The effects on food intake and body weight gain were
observed in two different experiments using either single icv AgRP
injections or continuous icv AgRP infusion. These effects were not
observed in icv saline-treated rats in either experiment and
animals receiving TTP2515 consumed food and appeared to
behave normally.
Subsequent experiments utilized TTP2515 in mouse models to
investigate its effects on endogenous AgRP. Although TTP2515
did not reduce food intake, body weight gain or adiposity in lean
wild-type mice at either the 30 mg/kg or 50 mg/kg dose, in DIO
mice, TTP2515 effectively reduced these parameters. This is
consistent with the expected actions of an AgRP inhibitor resulting
in increased MC4-R activity. These effects are similar to what has
been reported in DIO mice overexpressing MSH [6]. However,
the effects of TTP2515 on food intake and body weight could not
be solely attributed to AgRP inhibition as an attenuation in these
parameters was also observed in DIO AgRP KO mice treated with
TTP2515. There was a tendency for WT TTP2515 treated mice
to lose more weight than KO TTP2515 treated mice, but this was
not significant. However, WT TTP2515 mice gained significantly
less fat mass during the experiment compared to KO water mice,
while the KO TTP2515 and water treated mice gained more
similar amounts, suggesting that TTP2515 is somewhat more
effective in WT mice in preventing fat mass accretion, compared
to KO DIO mice. Furthermore, a significant decrease in RQ
during the light cycle was also noted in TTP2515 treated DIO
mice, consistent with predicted changes in adiposity and energy
partitioning that might be expected with AgRP inhibition. The
effects of TTP2515 on RQ noted in WT mice during the light
cycle were not observed when KO mice were treated with either
30 mg/kg or 50 mg/kg TTP2515. This data suggests that the
effects of TTP2515 on energy partitioning may be specific for
AgRP antagonism and is consistent with findings from a report on
AgRP KO mice [18]. In contrast to what would be predicted,
TTP2515 treated DIO mice displayed a transient decrease in
VO2 and EE which could be explained by the concomitant
unexpected decrease in physical activity observed. In fact, if
adjusted for activity, VO2 and EE were no longer suppressed in
TTP2515 treated mice. These transient effects on VO2, EE and
activity were also evident in TTP2515 treated AgRP KO mice and
thus could not be attributed to AgRP antagonism. These transient
effects on VO2, EE and activity were not observed in ob/ob mice,
however this was likely due to their inherently low baseline levels.
Thus, TTP2515 treatment reduced food intake, body weight gain
and adiposity in both AgRP KO and WT mice on a HFD, but not
in mice on a chow diet and reductions in adiposity and RQ
observed in HFD fed mice appeared to be more pronounced in
WT than KO mice.
TTP2515 was extremely effective in preventing weight gain in
obese leptin-deficient mice on a chow diet; leptin-deficient mice
are reported to have elevated hypothalamic AgRP expression [12].
Significant, dose-dependent reductions in food intake and body
weight gain as well as decreases in adiposity and RQ were noted in
these mice. It is unknown if these effects are specific for AgRP
antagonism as we did not study leptin-deficient AgRP KO mice.
However, the same 50 mg/kg dose that potently reduced food
intake, weight gain, and fat mass accretion in ob/ob mice failed to
modulate any of these parameters in lean wild-type mice on a
chow diet. These data suggest that the effects observed in ob/ob
mice could be due to AgRP antagonism.
TTP2515 was quite effective under fasting conditions where
AgRP expression in the hypothalamus is increased [11,13,31].
Dose response studies show that TTP2515 can attenuate rebound
feeding in mice at both a 25 mg/kg and 50 mg/kg dose. At
25 mg/kg TTP2515 attenuated rebound feeding and weight gain
in WT mice, but not in KO mice, and at the 50 mg/kg dose,
TTP2515 attenuated cumulative body weight gain in WT mice,
but not KO mice, indicating that these effects appear to be
relatively specific for AgRP antagonism. As attenuated rebound
feeding at the 50 mg/kg dose was observed in both KO and WT
mice, this suggests that higher doses may yield non-specific effects.
Furthermore in lean BL6 mice, TTP2515 treatment attenuated
fasting-induced increases in activity. This is in agreement with
previous data that has shown that activating the AgRP neuron
drives food-seeking behavior [19]. Unfortunately, activity was not
studied in AgRP KO mice during fasting.
Several lines of evidence demonstrate a role for the melano-
cortin system in modulating the hyperphagic response initially
observed after switching mice to a high diet. First, switching BL6
mice from a normal chow diet to a higher fat diet (42–45%)
produces an initial hyperphagic response that is quickly downreg-
ulated [30,34]; however MC4-R knockout mice are unable to
downregulate their food intake after initiation of a higher fat diet
[30,34]. Secondly, AgRP increases fat intake [35,36], while MTII
decreases preferential fat consumption [36–38]. Furthermore,
Agouti-overexpressing (Ay) mice and MC4-R KO rats have an
increased preference for fat [39,40]. In addition, AgrpmRNA levels
decline after mice are switched to a HFD [41]. We therefore
Figure 7. Effects of TTP2515 in WT or AgRP KO mice acutely switched to a very high-fat diet. (A–F) Mice were switched from breeder
chow to a 60% fat diet and started treatment with TTP2515 (30 mg/kg) or water twice daily. (A–C) Cumulative food intake, cumulative weight gain
and fat mass were all significantly lower in TTP2515 treated mice. (D) Total T4 levels were significantly higher in TTP2515 treated mice. (E) Leptin
levels tended to be lower in TTP2515 treated mice (p = 0.12). (F) Insulin levels were similar between groups. (G–J) In a separate experiment, AgRP KO
mice on a 10% fat chow diet were switched to a 60% fat diet and started treatment with TTP2515 (5, 15, or 30 mg/kg) or water twice daily. (G,I)
Cumulative caloric intake and cumulative weight gain were dose-dependently lower in TTP2515 treated mice compared to the water group. (H) Fat
mass was lower in TTP2515 treated mice at both the 15 and 30 mg/kg doses vs. water. The 5 mg/kg group tended (p = 0.05) to have lower fat mass
than the water group. (J) After 5 days of treatment, total T4 levels were equivalent between groups, however fasting and continued treatment
revealed an increase in total T4 levels. *p,0.05, **p,0.01 vs water; ap,0.05 vs water, bp,0.05 vs 5 mg/kg, cp,0.05 vs 15 mg/kg.
doi:10.1371/journal.pone.0065317.g007
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hypothesized that TTP2515 would be particularly effective in
attenuating the acute effects after initiation of a HFD. Introduction
of the 60% HFD to mice that simultaneously started TTP2515
treatment significantly reduced caloric intake; this reduction was
significant compared to both baseline chow diet intake and versus
water treatment. Mice treated with TTP2515 recover after
approximately 3 days and resume normal daily food intake,
however lower cumulative food intake and body weight gain
persisted in TTP2515 treated mice after 5 days. This effect is quite
remarkable given that mice maintained on a breeder chow diet
and administered TTP2515 treatment are unaffected by the
compound. This data suggests that TTP2515 has a potent effect
on fat intake. However, surprisingly, TTP2515 was equally
effective when the same experiment was conducted in AgRP
KO mice. Thus, this effect is not due to AgRP antagonism. The
dose-responsive effect observed in KO mice suggests that
TTP2515 may bind to a similar, perhaps yet unknown, target
which strongly promotes fat intake. As the effect on fat intake was
initiated rapidly and with such potency, it suggests that TTP2515
could potentially have a local effect in the gut in the presence of
increased dietary fat, which could lead to the suppression of food
intake. Regardless of the mechanism, these results are of interest as
compounds that promote decreased dietary fat intake may have
clinical utility.
It was also predicted that an AgRP inhibitor would increase
thyroid hormone levels under certain conditions given the role that
AgRP plays in regulating the thyroid axis and mediating the
fasting induced suppression of T4 and T3 levels [8,16,17].
Additionally, in one study, AgRP KO mice were reported to
have higher total T4 and T3 levels [18]. In the current study icv
AgRP suppressed plasma T4 levels (as expected), however this
suppression was prevented by TTP2515 treatment. TTP2515 also
increased total and free T4 levels in lean and DIO mice when
animals were treated for at least 4 days. T4 was also increased after
TTP2515 treatment in fasted mice, however this was only
observed in an experiment when the drug was administered for
4 days and not when administered for a shorter duration (1.5
days). Of note, TTP2515 had no effect on T3 levels at any time in
any experiment. T4 measurements are notoriously subject to
technical problems with a variety of assays, especially in the
presence of drugs that can affect binding proteins and assay
performance, hence the validity of these T4 measurements may
come into question. In any case, the effects of TTP2515 on T4
levels are not specific for AgRP antagonism; we showed that both
TTP2515 treated KO and WT mice had elevated free and total
T4 levels compared to KO mice receiving water treatment.
Previous studies have utilized genetic models of AgRP deletion
or AgRP neuronal ablation to uncover AgRP’s effects on energy
balance and metabolism. However, the interpretation of these
studies is complicated by developmental compensation and the loss
of other neurotransmitters from AgRP neurons [18,21,23]. This is
the first report of a pharmacological inhibitor of the AgRP peptide
that could be used to help elucidate the role of AgRP in regulating
energy homeostasis. The effects of TTP2515 are most prominent
under conditions in which AgRP is known to be elevated such as
during fasting and with leptin deficiency [11–13,31]. TTP2515
also affected feeding and metabolic responses after acute or
chronic exposure to a HFD, conditions that can be modulated by
the melanocortin system. Although TTP2515 demonstrated some
clear off-target effects in AgRP KO mice, there was some relative
specificity to the effects on adiposity and RQ as well as on
refeeding after fasting, which are consistent with AgRP’s
orexigenic and metabolic function. The cause of the off-target
effects are at present unclear. It is of interest that most of the non-
AgRP mediated effects observed are still consistent with what
would be expected with stimulation of the melanocortin system. It
may be that TTP2515 also binds to a peptide of similar function to
AgRP that modulates food intake, energy balance and preference
for fat intake. Although Agouti is a potential candidate as it
possesses 25% sequence homology to AgRP [12], in mice it is
expressed in the skin, functions in a paracrine manner and is not
known to regulate energy balance unless ectopically expressed as
in mice with the Ay mutation [42]. However, interaction with
other related peptides or non-peptides is clearly possible. Future
studies should be directed at uncovering the mechanism by which
TTP2515 yields such potent effects favoring negative energy
balance, even in the absence of AgRP.
The rationale for using an AgRP inhibitor, rather than an
MC4-R agonist, to increase melanocortin signaling relates to the
fact that AgRP neuronal projections are more restricted to brain
areas regulating energy balance; hence this inhibitor will affect
only a subset of MC-Rs, compared to the wide distribution of
brain MC4-Rs that would be affected by an MC4-R agonist
[25,26]. Although MSH agonists are effective, they have been
associated with a number of side effects including increased blood
pressure, due to the extensive distribution of brain MC-Rs [29].
Furthermore, an AgRP inhibitor has the potential to be utilized in
a therapeutic capacity, particularly under conditions in which
AgRP levels are elevated. In humans, this might be utilized
optimally during diet and weight loss or during weight mainte-
nance after weight loss has been achieved. Additionally, the potent
effect of TTP2515 on fat consumption suggests that this peptide
could also be advantageous before consuming a fat-rich meal, to
attenuate HFD food intake.
In summary TTP2515 functions in vitro as an AgRP inhibitor,
and when administered orally exerts numerous metabolic effects
in rats and mice. Many of these effects are consistent with
AgRP inhibition, yet in some cases are evident in AgRP null
mice indicating off target effects of this drug. TTP2515 is most
effective in obese models including DIO and ob/ob mice, as well
as during consumption of a HFD and does not cause weight
loss in lean mice on a low fat diet. Thus the usefulness of this
drug in treating human obesity deserves further exploration.
Future studies are needed to define the AgRP dependent and
independent mechanisms by which this drug exerts its effects on
energy balance.
Figure 8. Effects of TTP2515 on refeeding and T4 after fasting in AgRP KO andWTmice. (A–F) AgRP KO and WT mice were fasted for 24 h
and received either water or TTP2515 at 10, 25, or 50 mg/kg in three different experiments. (A,B) At the 10 mg/kg dose, no differences in food intake
or body weight gain were observed. (C,D) At the 25 mg/kg dose, there was an overall significant attenuation in food intake (p,0.05) and weight
gain (p,0.01) in the WT TTP2515 vs. the WT water group. Post-hoc analysis revealed that this was significant at the 20 h for food intake and at 9 and
20 h for weight gain. No differences in food intake or weight gain were observed between the KO TTP2515 vs KO water group. (E) At the 50 mg/kg
dose, there was an overall significant attenuation in food intake in both the WT TTP2515 (p,0.01) and KO TTP2515 (p,0.05) groups vs. their water
controls. Final cumulative food intake at the 20 h timepoint was significantly less in both TTP2515 groups vs. their water groups. (F) At the 50 mg/kg
dose, final cumulative weight gain at 20 h was significantly less only in the WT TTP2515 vs WT water group. (G) A separate group of mice was fasted
and blood samples were obtained before and after treatment. No difference in total T4 levels were observed before or after treatment. ***p,0.0001,
**p,0.01, *p,0.05 vs respective water control.
doi:10.1371/journal.pone.0065317.g008
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